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Stem cell-derived hepatocyte-like cells (HLCs) offer great opportunities for studies of host-pathogen 14 
interactions and tissue regeneration, as well as hepatotoxicity. To reliably predict the outcome of 15 
infection or to enhance graft survival, a finely tuned innate immune system is essential. Hepatocytes 16 
have long been considered solely metabolic and their critical innate immune potential is only 17 
recently gaining attention. Viral infection studies show that pathogen detection by cytosolic 18 
receptors leads to interferon (IFN) induction in primary hepatocytes and HLCs. IFN expression in 19 
HLCs is characterised by strong expression of type III IFN and low expression of type I IFN which is 20 
also a characteristic of primary hepatocytes. The response to IFN differs in HLCs with lower 21 
interferon-stimulated gene (ISG)-expression levels than in primary hepatocytes. TNF-α signalling is 22 
less studied in HLCs, but appears to be functional. Expression of toll-like receptors (TLR) 2-5, 7 and 9 23 
have been reported in primary hepatocytes but have been poorly studied in HLCs. In summary, 24 
although they retain some immature features, HLCs are in many ways superior to hepatoma cell 25 
lines for cell based modelling. In this review, we will provide an overview of innate immune signalling 26 
in HLCs and how this compares to primary hepatocytes. 27 
 28 
Key words: Stem cells, hepatocytes, innate immunity 29 
 30 
 31 
1. Introduction 32 
Stem cell-derived hepatocyte-like cells (HLCs) are of interest as alternatives to primary cells for the 33 
study of host-pathogen interactions, tissue regeneration and drug-development. The discovery of 34 
somatic cell reprogramming in 2006, which allows the generation of pluripotent stem cells, has 35 
revolutionised the field of stem cell research. The so-called induced pluripotent stem cells (iPSCs) 36 
can be produced from the desired genetic background providing diverse stem cell banks (1). In 37 
contrast, human embryonic stem cells (hESC) are derived from the inner cell mass of 38 
preimplantation embryos that are not suitable for human implantation, with the first hESC lines 39 
described in 1998 (2). Currently, both hESC and iPSC are used in stem cell research and for 40 
differentiation into somatic cells. 41 
 42 
The immunogenicity of pluripotent stem cell-derived HLCs and other somatic cells has been studied 43 
extensively while the ability of in vitro differentiated HLCs to mount an immune response by sensing 44 
and reacting to pathogens has only recently gained attention (3-13). As the major metabolic cell type 45 
of the liver, hepatocytes are constantly exposed to diverse metabolic products and antigens 46 
including the products of digestion as well as hepatotrophic pathogens. In this microenvironment 47 
the hepatocyte has to be immune tolerant to food- and commensal-derived antigens while staying 48 
alert to invading pathogens. To manage the dichotomy between immune tolerance and immune 49 
activation, the hepatic innate immune system is tightly regulated. In vitro differentiated HLCs that 50 
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closely mimic primary hepatocytes would be of significant value in identifying these regulatory 51 
mechanisms. 52 
 53 
Studies of host-pathogen interactions have long relied on hepatoma cell lines where innate immune 54 
responses are impaired and intracellular signalling is not representative of healthy hepatocytes (3, 4, 55 
14-16). HLCs more closely mimic the in vivo situation. Moreover, as they possess the genetic 56 
background of their donor, HLCs can be used to study donor specific influences on hepatocyte 57 
function (17). Hence, HLCs are a promising tool for understanding cell-based immune responses to 58 
pathogens and provide a platform for identification of the mechanisms that underlie inter-individual 59 
differences in susceptibility to hepatotrophic pathogens.  60 
 61 
Discovering host genetic factors that determine the outcome of hepatotrophic infections and 62 
response to antiviral therapy will also lay the basis for the development of new and better therapies 63 
with fewer side effects. Host factors important for viral entry and replication, viral sensing 64 
mechanisms and the induction of innate immune responses in infected cells all together determine 65 
the outcome of infection. For viruses that establish chronic infection such as hepatitis B (HBV) and 66 
hepatitis C virus (HCV) the effectiveness of the innate immune response mounted by the host cell 67 
determines whether infection becomes chronic or is cleared successfully (18-21). In order to enhance 68 
the hosts’ innate immune response and thereby increase the chances of clearing the virus, immune-69 
based therapies are of continued interest for the treatment of HBV and HCV. At the same time, 70 
these therapies are of benefit for the treatment of viruses with high genetic variation such as HCV 71 
(22). 72 
 73 
With regard to regenerative medicine, functional innate immune responses in stem cell-derived 74 
somatic cells to be used for transplantation will improve graft survival and allow the cells to react to 75 
and fight off invading pathogens. A tightly regulated immune response is particularly important in 76 
the liver, an organ that is constantly exposed to a wide variety of antigens including both, food-77 
derived antigens and pathogens (23).  78 
This review will provide an overview of our current knowledge of the innate immune machinery of 79 
stem cell-derived HLCs and how it compares to primary hepatocytes. Expression of viral sensing 80 
molecules, downstream signalling pathways and generation of antiviral and pro-inflammatory 81 
cytokines will be discussed in relation to the in vivo situation with the aim of better understanding 82 
the immune phenotype of in vitro differentiated HLCs. 83 
 84 
 85 
2. Innate immune pathways in SC-derived hepatocytes 86 
Protein-based innate immune responses, such as virus sensing by pattern recognition receptors 87 
(PRR) and the interferon response are not detectable in pluripotent cells and are only acquired 88 
during maturation (5, 24, 25). Innate immunity in pluripotent stem cells was therefore long thought 89 
to be severely attenuated. However, more recent studies of defense strategies of pluripotent stem 90 
cells suggest RNAi as a major antiviral mechanism (5, 24, 25). In contrast, innate immune strategies 91 
in differentiated cells comprise detection of pathogen-associated molecular patterns (PAMPs), 92 
which are conserved structures within a pathogen, by PRRs followed by expression of IFN and ISGs 93 
and intrinsic antiviral immunity. 94 
 95 
Despite the progress made in differentiation procedures, HLCs retain an immature phenotype, still 96 
expressing markers of stem cells and fetal hepatocytes (26, 27). It is therefore not farfetched to 97 
assume that innate immune pathways might also be of an immature phenotype in the in vitro 98 
differentiated cells. From the few studies that have investigated innate immunity in stem cell-99 
derived somatic cells, there is some evidence that the IFN-based arm of innate immunity and also 100 
toll-like receptor (TLR)-responses remain down-regulated (figure 2). However, research of these 101 
mechanisms in HLCs is still limited, requiring further studies into the antiviral response. In the 102 
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following section, we will describe hepatic innate immune mechanisms and their presence or 103 
absence in HLCs.  104 
 105 
 106 
2.1 Viral sensing by cytosolic PRRs 107 
Hepatocytes are equipped with a variety of cytosolic PRRs that allow them to detect PAMPs from 108 
DNA- and RNA- viruses, intracellular bacteria and damage-associated molecular patterns (DAMP), 109 
released from damaged cells. Retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-110 
associated gene 5 (Mda-5) are sensors of viral dsRNA. Ligand binding triggers a signalling cascade 111 
via mitochondrial antiviral signalling protein (MAVS) and interferon regulatory factor 3 (IRF3) 112 
leading to the induction of IFNs. While RIG-I senses short dsRNA motifs, long dsRNA is sensed by 113 
Mda-5. Ligand recognition of RIG-I or Mda-5 results in receptor recruitment to the mitochondrial 114 
surface where binding to MAVS via the respective CARD domains occurs. The complex of RIG-115 
I/MAVS and Mda-5/MAVS respectively activates TANK-binding kinase 1 (TBK-1) and IkB kinase-ε of 116 
the IkB kinase complex which phosphorylate IRF3. Phosphorylated IRF3 translocates to the nucleus 117 
and induces the expression of type I and type III IFNs (figure 1) (28). 118 
Viral DNA is detected by the cGAS-STING signalling pathway (29, 30). cGAS detects dsDNA and 119 
induces STING to recruit TBK-1 and IRF3 to its C-terminus. The close proximity between TBK-1 and 120 
IRF3 allows TBK-1 to phosphorylate IRF3 which ultimately leads to IFN-release. 121 
 122 
Infection studies with HCV and HBV revealed that cytoplasmic PRRs in HLCs, including RIG-I and 123 
cGAS, sense infection and mount an innate immune response against both RNA and DNA-viruses. 124 
The use of polyI:C to mimic dsRNA revealed that HLCs detect HCV-infection through RIG-I, resulting 125 
in strong upregulation of type III and weaker upregulation of type I IFNs (3, 6). Late and low level 126 
induction of type I IFNs is also characteristic of primary human hepatocytes. IL-29 was found to be 127 
the major IFN expressed by stem cell-derived hepatocytes upon HCV-infection and polyI:C 128 
stimulation, closely mimicking the in vivo situation (3, 31). Viral detection and subsequent IFN-129 
responses further upregulate PRR expression such as RIG-I, cGAS and STING in HLCs (3, 7). 130 
 131 
Genetic variation of IL28B, another type III IFN is associated with variation in response to therapy for 132 
HCV-infection (32). Expression of IL28 by HLCs upon HCV-infection implicates the potential of stem 133 
cell-derived hepatocytes to study the influence of host genetics on viral infection. Markedly, type III 134 
IFNs are not expressed by HCV-infected Huh7 cells, showing the superiority of HLCs for studies on 135 
host-pathogen interaction (3). 136 
 137 
 138 
2.2 Response to IFNs and the JAK/STAT pathway 139 
Type I and III IFNs are released by infected hepatocytes and demonstrate autocrine and paracrine 140 
activity, inducing an antiviral state in the local tissue. IFN-receptors are heterodimers of 141 
transmembrane proteins that contain an extracellular ligand binding domain and a cytoplasmic tail. 142 
Hepatocytes express receptors for type I and III IFNs; IFNAR1/IFNAR2 bind type I IFNs (IFN-α and 143 
IFN-ß) and IFNLR1/IL10-R2 bind type III IFNs (IFN-λ1/IL29, IFN-λ2/IL28A and IFN-λ3/IL28B). Upon 144 
binding of IFNs to their receptor, the cytoplasmic receptor-associated tyrosine kinases Janus kinase 145 
1 (JAK1) and Tyrosine kinase 2 (TYK2) become auto-phosphorylated. Phosphorylated JAK1 and 146 
TYK2 recruit and phosphorylate signal transducer and activator of transcription protein 1 (STAT1) 147 
and STAT2 which promotes their association with IRF9. The resulting complex of STAT1, STAT2 and 148 
IRF9 translocates to the nucleus where it binds to IFN-stimulated response elements (ISRE) on the 149 
DNA and induces expression of hundreds of ISGs (figure 1) (33). JAK/STAT signalling is negatively 150 
regulated by suppressor of cytokine signalling (SOCS1) which ubiquinates phosphorylated STAT1 151 
and mediates its proteasomal degradation. In differentiated cells, SOCS1 is expressed at low basal 152 
levels but as an ISG itself becomes rapidly upregulated upon induction of the JAK/STAT pathway. 153 
 154 
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hESC, iPSCs and derived HLCs express all components of the IFN-signalling pathway (IFNAR1,2, 155 
STAT1,2 IRF9) (24). However, hESCs and iPSCs lack the ability to respond to IFN-α treatment due to 156 
high basal SOCS1 levels (24). Responsiveness to IFN-α develops early on during differentiation, 157 
correlates with downregulation of basal SOCS1 levels and increases over time. D5-definitive 158 
endoderm, d15-hepatoblasts and d21-HLCs are all able to respond to IFN-α treatment with 159 
phosphorylation of STAT1 and expression of ISGs but mature HLCs show the strongest ISG-160 
induction levels (8, 10). The antiviral effect of the ISGs expressed by HLCs was confirmed in studies 161 
of HCV and HBV infection where IFN-α treatment of HLCs prior to virus infection significantly 162 
reduced viral replication and persistence (8, 10). 163 
 164 
With emerging evidence of the importance of IL29 in hepatocyte immunity, research focused on the 165 
expression and response to type III IFNs in HLCs. Indeed, HLCs respond to IL29 treatment with 166 
phosphorylation of STAT1 and expression of ISGs (IFIT1, Mx1, OAS1, ISG15, CXCL10, CXCL11, IRF9, 167 
IRF7, IRF1, IRF2) (3, 6). These findings show that pluripotent stem cell-derived hepatocytes possess 168 
functional IFN-signalling pathways which allow them to mount an innate immune response against 169 
invading pathogens that are representative of primary hepatocytes. 170 
 171 
However, virus-induced expression of IFNs and ISGs is still reduced when compared to primary 172 
hepatocytes. One study examined the presence of HBV cccDNA, a characteristic of persistent HBV-173 
infection, in HLCs and primary hepatocytes in the presence and absence of an inhibitor of the 174 
JAK/STAT pathway (JAKi). While cccDNA in primary hepatocytes was almost exclusively found in 175 
cells treated with JAKi, treated and also untreated HLCs harbored cccDNA. Examination of the 176 
innate immune response in HLCs revealed that although ISG-expression reflected ISG-expression in 177 
primary hepatocytes, gene expression was considerably lower in HLCs which explains why HBV 178 
cccDNA was detectable in HLCs despite an antiviral response of the cells. IL28B, IL29, IRF3, IRF9 179 
ISG15, ISG20 and Mx2 in d20 HLCs were only slightly upregulated compared to HBV-resistant d7 180 
cells (7). This observation may be representative of an immature immune response in HLCs, 181 
although, more studies are needed to better understand this finding. 182 
Studies of chronic viral infection might also benefit from HLCs having immature immune pathways. 183 
In HCV-infection for example, only a minority of HCV-positive hepatocytes is found in the in vivo 184 
situation (7-20%) and the infected cells seem to be of an immature phenotype (AFP+, EpCAM+) that 185 
appear in regenerating areas of the liver. While regenerating progenitor cells represent only a small 186 
proportion of cells in the liver, they contain high levels of HCV and it is assumed that they serve as a 187 
reservoir for HCV (34,35). Hence, to understand how hepatotrophic viruses like HCV develop chronic 188 
infection, HLCs with reduced PRR-expression and IFN-responses could be critical. 189 
 190 
HLCs can also be used to study immune evasion of hepatotrophic viruses. Upon dengue virus 191 
(DENV) infection, ISG-expression in infected HLCs was reduced when compared to surrounding 192 
uninfected HLCs. This shows that the virus counteracts innate immune responses to evade the 193 
immune mechanisms of the infected cells (13). 194 
 195 
 196 
2.3 Intrinsic Anti-Viral Mechanisms 197 
Intrinsic immunity describes destruction of the invading pathogen performed directly by the sensing 198 
molecule. Examples of intrinsic immunity are dsRNA-activated protein kinase R (PKR) and 199 
ribonuclease L (RNaseL). Although their expression is further upregulated by IFNs which classifies 200 
them as ISGs, they are already highly expressed in uninfected cells and upon infection can become 201 
immediately activated. PKR and RNaseL are both detectable in pluripotent stem cells, although PKR 202 
has been shown to be unresponsive to polyI:C and responsiveness develops in the course of 203 
differentiation (36). 204 
 205 
 206 
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3.4 TNF-α-pathway 207 
Tumor necrosis factor-alpha (TNF-α) is a key player in liver homeostasis that regulates proliferation, 208 
survival and cell death. TNF-α signals through NF-κB and C-Jun N-terminal kinase (JNK) and cell 209 
signalling is tightly regulated as an imbalance of these pathways results in liver diseases such as 210 
cancer development or hepatic failure (37). TNF-α has been shown to play a prominent role in the 211 
pathogenesis of chronic HCV- and HBV infection (37). 212 
 213 
TNF-α signalling through NF-κB promotes cell survival and induces expression of various 214 
proinflammatory cytokines while JNK-signalling induces apoptosis (14). Binding of soluble TNF-α to 215 
its receptor TNFR1 on the cell surface induces homotrimer formation of TNFR1. Adaptor protein 216 
TNFR-associated death domain (TRADD) is recruited and binds to the cytosolic region of the 217 
receptor. Upon receptor binding, TRADD interacts with the downstream signalling molecules TNF-α 218 
receptor-associated factor 2 (TRAF2) and receptor-interacting protein kinase (RIP). The complex of 219 
TRADD, TRAF2 and RIP can activate both, NFκB- and JNK-signalling, leading to either cell survival 220 
or death. NFκB is a heterodimer of the two subunits p65 and p50. In the quiescent state, IkB binds to 221 
NFκB, thereby inhibiting NFκB and preventing its nuclear localisation. TNF-α signalling activates the 222 
IκB-kinase (IKK) complex, consisting of the kinase subunits IKKα and IKKß and the regulatory 223 
subunit IKKγ. Phosphorylation of IKKß activates the complex and induces IκBα degradation via Ser 224 
32 and 36 phosphorylation which marks the protein for ubiquitination on Lys 21 and 22 and 225 
subsequent degradation by the proteasome 26S complex (38). Released from their association with 226 
IκB, NFκB heterodimers translocate to the nucleus where they transactivate pro-inflammatory 227 
cytokine expression, such as TNF-α, CXCL10, CXCL11 and IL-8 as well as pro-survival genes such as 228 
caspase-8 inhibitor c-FLIP and Gadd35ß. 229 
 230 
HLCs release TNF-α in response to infection and respond to stimulation with recombinant TNF-α. 231 
Hence, they represent a valuable opportunity to study TNF-α signalling in infection, proliferation 232 
and carcinogenesis. This will also help to better understand the mechanisms that regulate the 233 
interplay between TNF-α induced NFκB- and JNK-signalling and thereby the regulation of cell 234 
survival and cell death. Studies in this field had been hampered by the lack of an appropriate cell 235 
system. Although hepatoma cell lines such as Huh7 cells greatly contributed to our current 236 
understanding of cell cycle regulation, these cell lines represent cancer tissue. Deregulated cell 237 
death/survival pathways are the main feature of hepatoma cell lines, making these cells an 238 
unreliable model. The high survival capacity of Huh7 cells, for example, is promoted by high basal 239 
NFκB levels. Understanding the mechanisms that regulate cell death and survival would be of 240 
therapeutic value and could lead to the identification of therapies that prevent cell death in the 241 
context of liver injury or suppress carcinogenesis and HLCs could be of great value in these studies. 242 
Viral proteins such as dengue virus (DENV) NS1 can directly activate NFκB-signalling for TNF-α 243 
production in HLCs (13). DENV infection of hESC- and iPSC-HLC activates NFκB-signalling as 244 
determined by phosphorylation of the NFκB subunits p65/p50. As phosphorylation of p65/p50 was 245 
not limited to infected cells, NFκB activation does not only seem to be a result of direct virus-sensing 246 
but is also induced by the paracrine mechanism of TNF-α released from infected cells. NFκB-247 
activation resulted in synthesis and release of proinflammatory cytokines such as CXCL10, CXCL11, 248 
IL6 and to a smaller extent IL8 and TNF-α and downregulation of normal hepatocyte-genes such as 249 
albumin, E-cadherin, coagulation factor V and proteins of the complement system such as F5. 250 




2.5 TLR expression and downstream signalling pathways 255 
Toll-like receptors (TLR) are central in pathogen sensing and activation of immune responses. The 256 
TLR-response in hepatocytes is tightly regulated in vivo which is crucial in an organ that is constantly 257 
exposed to various antigens, including pathogens coming from the gut. In this microenvironment, 258 
Page 5 of 14
http://mc.manuscriptcentral.com/issue-ptrsb
































































the hepatocyte has to stay alert to invading pathogens and initiate appropriate immune responses 259 
while TLR over-activation is associated with pathogenesis of chronic inflammation and disease. In 260 
healthy hepatocytes mRNA for all TLRs is only marginally expressed but upon exposure to certain 261 
stimuli, specific TLRs can be upregulated (39). Further, TLR-signalling and deregulation influences 262 
carcinogenesis. It is therefore not surprising that TLR-expression in hepatoma cell lines is modified. 263 
TLR3 and 7 appears to be under expressed in hepatoma cell lines which makes these cells unsuitable 264 
for studies for TLR-responses to viruses and might explain why the role of TLRs in hepatocytes is 265 
often underestimated (40). 266 
 267 
PAMP recognition by a specific TLR induces signalling through NFκB, leading to the expression of 268 
numerous host defense genes. Nine functional TLRs are known in humans (TLR1-9). TLR3 (which 269 
detects dsRNA), TLR7 (which detects ssRNA) and TLR9 (which detects non-methylated DNA CpG-270 
motifs) are located within the endosomes of hepatocytes while TLR2, TLR4 and TLR5 are localized 271 
on the cell membrane. Binding of a ligand to its receptor triggers signalling via MyD88 for TLR2, 272 
TLR4, TLR5, TLR7/8 and TLR9 and TRIF for TLR3. MyD88 is anchored to the cytoplasmic TIR-domain 273 
of the TLR by its own TIR-domain. Activated MyD88 recruits interleukin 1 receptor associated kinase 274 
(IRAK), leading to IRAK auto-phosphorylation. Phosphorylated IRAK detaches from MyD88 and 275 
activates TRAF6 which then activates the IKK-complex resulting in NFκB translocation to the 276 
nucleus (see TNF-signalling) and expression of pro-inflammatory cytokines such as TNF-α, CXCL10, 277 
CXCL11 and IL-8 (41). While in professional immune cells such as plasmacytoid dentritic cells, TLR7/8 278 
and TLR9 also signal via IRF7, leading to IFN-α and IL29 expression; data as to whether hepatocytes 279 
possess the IRF7 arm of TLR-signalling are conflicting. A study in HepG2 cells reported absence of 280 
IRF7 signalling upon TLR7 stimulation (42). However, as mentioned before, hepatoma cell lines are 281 
of limited value in the study of TLR-responses. HLCs would be of great benefit if expression of TLR-282 
proteins and components of the signalling pathways are expressed at the end of the differentiation 283 
procedure. 284 
 285 
TLR-expression by pluripotent stem cell-derived somatic cells has been studied but with the 286 
exception of Sakurai and colleagues who detected TLR3 mRNA expression in iPSC-derived 287 
hepatocytes, none of these examined HLCs (6). Földes and colleagues investigated responsiveness 288 
of hESC, hESC-derived endothelial cells (hESC-EC) and primary human endothelial cells to ligands 289 
for TLR1-9 (43). In contrast to primary cells, neither hESC nor hESC-ECs responded to TLR-agonists 290 
with the exception of TLR5 which was already expressed in hESC. This lack was attributed to the 291 
absence of TLR-protein expression as stimulants that likewise signal through NFκB but act through 292 
different receptors (TNF-α, IL-1ß, IFN-y) induced IL8 expression in all three cell lines. qPCR-analysis 293 
revealed very low expression of TLR mRNA in hESC-EC and especially hESCs. Amounts of NFκB 294 
protein were comparable between hESC, hES-ECs and primary endothelial cells and increased only 295 
marginally in the course of differentiation. NFκB-signalling could be induced upon TNF-α, IL-1ß and 296 
IFN-y stimulation. This finding shows that hESC-derived ECs do not express TLRs although 297 
inflammatory signalling pathways are present and functional in hESCs and hESC-ECs. Markedly, in 298 
vivo conditioning of hESC-ECs by injection into nude mice for 21 days did not establish TLR-299 
expression (44). 300 
In contrast, two studies on hESC-derived fibroblasts and keratinocytes reported expression of TLR2 301 
and 4 and responsiveness to Gram-negative bacteria (45, 46). However, both TLRs were already 302 
expressed in hESC and responsiveness to bacterial challenge in hESC-fibroblasts appeared to be less 303 
specific compared to primary cells (45). 304 
 305 
The discrepancies amongst published data emphasis the importance of studying TLR-expression in 306 
stem-cell derived somatic cells more closely. Inducibility of TLR-expression and signalling in HLCs is 307 
of particular interest as tightly regulated hepatic TLR-responses in vivo are critical to maintain the 308 
balance between immune activation and tolerance in the liver. In primary hepatocytes, virus-309 
induced downregulation of TLR7 has been reported, further emphasising the need to study TLR-310 
responses in HLCs (47). 311 
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We are currently examining expression and inducibility of endosomal TLRs in HLCs from different 312 
backgrounds. As TLR responses develop late in the embryo and are again repressed after birth, 313 
deriving hepatocytes with functional TLR-responses from hESCs can be challenging. iPSCs might be 314 
of advantage here, considering their somatic cell origin. Indeed, expression and responsiveness of 315 
TLR2 and 4 has been detected in iPSC-derived endothelial cells while absence of TLR-expression in 316 
hESC-ECs was confirmed in this study (44). 317 
 318 
2.6 Acute Phase Protein (APP) Production 319 
The acute phase response describes a systemic immune response against sepsis where hepatocytes 320 
secrete defensive proteins into the circulation. The acute phase is initiated by inflammatory 321 
cytokines including IL-1ß, TNF-α and IL-6 which become upregulated upon inflammation. IL-6 322 
induces secretion of C-reactive protein, α1-antichymotrypsin, serum amyloid A and fibrinogen while 323 
secretion of albumin, transferrin and fibronectin becomes downregulated. 324 
However APP production by pluripotent stem cell-derived hepatocytes has not been studied 325 
extensively. Irudayam and colleagues analysed gene expression of acute phase proteins during 326 
hepatic differentiation of hESC and found a 10 to 1,000 fold upregulation of genes coding for acute 327 
phase proteins, coagulation factors and several members of the acute phase response such as serum 328 
amyloid A1, α1-antitrypsin and α2-macroglobulin in HLCs compared to definitive endoderm (9). 329 
However, only basal expression of acute phase proteins was examined and the results were not 330 
compared to primary hepatocytes. LPS- or IL6- induction of the acute phase response in HLCs has 331 
not been tested. It is therefore difficult to determine whether the acute phase response seen in HLCs 332 
is fully representative of the in vivo situation meriting further investigation. 333 
 334 
 335 
3.0 Conclusion 336 
In vitro differentiated cells such as HLCs, endothelial cells, cardiomyocytes, smooth muscle cells and 337 
osteoblasts differ from their in vivo counterparts in numerous ways. This includes the innate immune 338 
response. This immature phenotype is characterised by reduced levels of ISG-expression upon 339 
infection or stimulation with TLR-ligands. Production of IFNs upon infection and ISG-expression are 340 
the major innate immune mechanisms in hepatocytes. These pathways have been shown to be 341 
expressed in HLCs. However, other pathways also play important roles in the clearance of infection. 342 
Studies on HBV-infection of primary hepatocytes from different donors reported huge variation in 343 
virus susceptibility and in some cases even suppression of the IFN-based immune responses could 344 
not reconstitute virus replication (7). This shows that other pathways of the innate immune response 345 
play a role in susceptibility to disease, highlighting that IFN pathways in HLCs alone are not 346 
sufficient to study inter-individual differences in virus susceptibility. This finding also demonstrates 347 
that it is necessary to improve differentiation protocols to deliver intact innate immune pathways in 348 
HLCs, to allow further mechanistic studies. One strategy to improve maturation of innate immune 349 
pathways could be the addition of immunostimulatory cytokines to the differentiation medium as is 350 
standard for the differentiation of immune cells such as natural killer cells and dentritic cells. Innate 351 
immune pathways in these cells are more developed than in tissue cells. 352 
 353 
The lack of certain pathways of the innate immune response such as TLR-signalling might have 354 
important implications for tissue regeneration, drug-testing and host-pathogen studies. For studies 355 
on host-pathogen interaction, mature immune signalling will be essential while for regenerative 356 
medicine, immature immune signalling can be beneficial in certain cases, including transplant 357 
acceptance. Pathogens are generally detected by more than one sensing molecule, for example 358 
TLR4 and the cytoplasmic receptor NOD-I both sense Gram-negative bacteria. In contrast to NOD-I, 359 
TLR4 is also associated with vascular inflammation in endothelial cells and hESC-ECs that do not 360 
express TLR4 sense Gram-negative bacteria by NOD-I and mount comparable levels of antiviral 361 
cytokines. hESC-ECs that lack TLR-responses might therefore be a promising target for 362 
transplantation into patients with atherosclerosis (44). The same would apply to situations where 363 
tissue or organ damage is a result of excessive immune responses. 364 
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In conclusion, pluripotent stem cell-derived HLCs are superior to hepatoma cell lines for mimicking 366 
hepatic innate immunity. However, innate immunity is compromised in HLCs when compared to 367 
primary hepatocytes (figure 2) necessitating future improvements in cellular differentiation 368 
protocols from PSCs.  369 
 370 
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Figure 1: Innate immune signalling pathways in hepatocytes. Hepatocytes possess sensors for DNA- and 521 
RNA viruses in the cytoplasm and in endosomes which, upon activation, induce the expression of IFNs and 522 
inflammatory cytokines. IFNs act in an autocrine and paracrine manner turning the cells into an antiviral state. 523 
Upon receptor binding of TNF-α signalling via NFkB leads to expression of inflammatory cytokines and 524 
chemokines. 525 
Abbreviations: ds – double stranded, RIG – retinoic acid inducible gene, Mda – melanoma differentiation 526 
associated gene, MAVS - mitochondrial antiviral signalling protein, TBK – tank-binding kinase, IRF – interferon 527 
regulatory factor, TLR – toll-like receptor, IRAK – interleukin 1 receptor associated kinase, TRAF - TNF-α 528 
receptor-associated factor, IFN – interferon, STAT – signal transducer and activator of transcription protein, 529 
ISRE – IFN-stimulated response element, TNF-α – tumor necrosis factor alpha, TNFR – tumor necrosis factor 530 
receptor, NFκB - nuclear factor kappa-light-chain-enhancer of activated B cells, IL –interleukin, CXCL10 - C-X-531 
C motif chemokine 532 
 533 
 534 
Figure 2: Comparison of innate immune pathways in pluripotent stem cells, stem cell-derived 535 
hepatocytes and primary hepatocytes. Pluripotent stem cells and primary hepatocytes employ 536 
fundamentally different mechanisms to defend themselves against invading pathogens. Innate immune 537 
pathways in HLCs resemble primary hepatocytes, however, reduced levels of ISG-expression and possible 538 
absence of TLR-responses represent immaturity of immune signalling pathways. 539 
Abbreviations: HLC –hepatocyte-like cells, ISG – interferon stimulated genes, PRR – pattern recognition 540 
receptor, SOCS - suppressor of cytokine signalling, NFκB - nuclear factor kappa-light-chain-enhancer of 541 
activated B cells, RIG – retinoic acid inducible gene, Mda – melanoma differentiation associated gene, IFN – 542 
interferon, ISG- interferon stimulated genes, IL – interleukin, TNF-α – tumor necrosis factor alpha CXCL - C-X-543 
C motif chemokine, TLR – toll-like receptor. 544 
 545 
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